COX-2 inhibitor for the treatment of idiopathic stabbing headache secondary to cerebrovascular diseases.
The idiopathic stabbing headache (ISH) is characterized by a stabbing pain of short duration, variable localization and an errant evolution pattern. As its biological mechanisms are unknown and the treatment options are little effective, this disorder shows a strong impact on the patient's life. Two females and one male, aged 76, 66 and 72 years, respectively, started presenting ISH within 20 days after the onset of a stroke. All the patients were treated for the ISH with celecoxib, a COX-2 specific inhibitor, with full recovery from ISH up to 6 days after it was first administered. The interruption of the drug 60 days after the treatment with celecoxib induced again the appearance of algic symptoms in two patients. We concluded that cerebrovascular diseases (CD) can lead to ISH and that the COX-2 inhibitor can be an effective prophylactic drug for ISH after CD.
Piovesan
E J
EJ
Headache Section, Neurology Unit, Internal Medicine Department, Hospital de Clinicas da Universidade Federal do Paraná, Curitiba, Brazil. piovesan@avalon.sul.com.br
Zukerman
E
E
Kowacs
P A
PA
Werneck
L C
LC
D000368:Aged; D002545:Brain Ischemia / Q000150:complications / Q000188:drug therapy / Q000201:enzymology; D000068579:Celecoxib; D002561:Cerebrovascular Disorders / Q000150:complications* / Q000188:drug therapy* / Q000201:enzymology; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D005260:Female; D006261:Headache / Q000188:drug therapy* / Q000201:enzymology / Q000209:etiology*; D006801:Humans; D002546:Ischemic Attack, Transient / Q000150:complications / Q000188:drug therapy / Q000201:enzymology; D007527:Isoenzymes / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008297:Male; D008565:Membrane Proteins; D010291:Paresis / Q000150:complications / Q000188:drug therapy / Q000201:enzymology; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D011720:Pyrazoles; D013449:Sulfonamides / Q000627:therapeutic use*
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D011720:Pyrazoles; D013449:Sulfonamides; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D000068579:Celecoxib